Spartalizumab: all 47 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's DiseaseRecruitingNCT07157345Phase 1
• A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) PatientsCompletedNCT04581343Phase 1Results posted
• Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)TerminatedNCT04390763Phase 2Results posted
• Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsTerminatedNCT04323436Phase 2Results posted
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
• Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic CancerCompletedNCT04191421Phase 1/2Results posted
• Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCompletedNCT03647488Phase 2Results posted
• A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast CancerCompletedNCT03499899Phase 2Results posted
• PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedNCT02967692Phase 3Results posted
• Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)CompletedNCT02955069Phase 2Results posted
• A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid TumorsTerminatedNCT02829723Phase 1/2Results posted
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedNCT02807844Phase 1/2Results posted
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT02608268Phase 1/2Results posted
• Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT02605967Phase 2Results posted
• Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02460224Phase 1/2Results posted
• Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/2Results posted
• Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedNCT04294160Phase 1
• Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid TumorsTerminatedNCT04237649Early Phase 1
• Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1
• Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study TreatmentsActive, not recruitingNCT04058756Phase 1
• A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCompletedNCT04028245Early Phase 1
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedNCT04000529Phase 1
• PDR001 + Panobinostat for Melanoma and NSCLCWithdrawnNCT03982134Phase 1
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingNCT03891953Phase 1
• Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the EsophagusStatus unknownNCT03785496Phase 2
• PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic AbnormalitiesStatus unknownNCT03693326Phase 2
• Dabrafenib + Trametinib + PDR001 In Colorectal CancerStatus unknownNCT03668431Phase 2
• PDR001 Plus Imatinib for Metastatic or Unresectable GISTCompletedNCT03609424Phase 1/2
• Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT03301896Phase 1
• PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal CancerTerminatedNCT03176264Phase 1
• Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT03172936Phase 1
• Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedNCT03111992Phase 1
• Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
• Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
• Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular PatientsCompletedNCT02988440Phase 1
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02947165Phase 1
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.TerminatedNCT02936102Phase 1
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
• Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and LymphomasCompletedNCT02740270Phase 1
• Phase I Study of PDR001 in Patients With Advanced Malignancies.CompletedNCT02678260Phase 1
• A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic CancersTerminatedNCT02452268Phase 1

← Spartalizumab overview